Sensitive and selective quantification of elcatonin in equine plasma and urine using LC-FAIMS-MS/MS.

Research Overview

• This study developed a highly sensitive and selective method to measure the drug elcatonin in horse plasma and urine to support doping control in horse racing and equestrian sports.
• The researchers optimized sample preparation and employed advanced mass spectrometry techniques, achieving very low detection limits and validating the method’s accuracy and reliability.

Background and Significance

• Elcatonin is a synthetic peptide that strengthens bones and relieves pain.
• Its use is banned in horse racing and equestrian sports due to potential performance enhancement.
• Detecting elcatonin is challenging because it has a complex cyclic structure and high molecular weight, making it difficult to analyze reliably using conventional methods.

Method Development

• The team developed a method combining liquid chromatography (LC) with high-field asymmetric waveform ion mobility spectrometry (FAIMS) and tandem mass spectrometry (MS/MS).
• This advanced combination improves the separation and detection of complex molecules like cyclic peptides.
• Sample preparation was optimized using weak cation exchange solid-phase extraction to isolate elcatonin effectively from plasma and urine samples.

Validation Procedures

• The method was validated through several criteria:
• Linearity: The method showed excellent linear response (R > 0.9995) in both plasma and urine samples.
• Reproducibility: Repeat tests confirmed consistent results.
• Sensitivity: The detection limit was very low, at 10 pg/mL, indicating high sensitivity.
• Selectivity: The method specifically detected elcatonin without interference from other substances.
• Recovery: Efficient extraction and detection of elcatonin from biological matrices.
• Analyte Stability: The stability of elcatonin was confirmed, including resistance to enzymatic or proteolytic degradation.

Pilot Pharmacokinetic and Pharmacodynamic Study

• After administering elcatonin, the drug was detectable in horse plasma for up to 6 hours but was not found in urine samples.
• Pharmacodynamic analysis recorded a small, transient decrease in plasma calcium levels following elcatonin administration.
• No adverse clinical effects such as hypocalcemia (low calcium levels with symptoms) were observed during the study period.

Implications and Conclusions

• The study successfully addressed challenges associated with detecting cyclic peptide drugs like elcatonin in complex biological samples.
• The validated method can be employed for anti-doping tests in horses, improving regulatory compliance.
• The approach may be applicable to other similar peptides, enhancing detection capabilities in doping control and veterinary medicine.